Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Broncus Holding's total equity for the quarter that ended in Jun. 2026 was HK$1,119.95 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
The historical data trend for Broncus Holding's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding (HKSE:02216) has a Total Equity of HK$1,119.95 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Broncus Holding and its competitors.
Is Broncus Holding's Total Equity too high?
Broncus Holding's current Total Equity is HK$1,119.95 Mil. Overall, Broncus Holding has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's Total Equity compare to ABT and SYK?
Broncus Holding's Total Equity of HK$1,119.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Broncus Holding and its competitors. Broncus Holding's current Total Equity is HK$1,119.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Based on GuruFocus' analysis, Broncus Holding (HKSE:02216) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.66 — trading 336.7% above its estimated fair value. The current Total Equity is HK$1,119.95 Mil. Broncus Holding's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Broncus Holding (HKSE:02216), the current Total Equity is HK$1,119.95 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Broncus Holding (HKSE:02216) Overvalued in 2026?
Based on GuruFocus' analysis, Broncus Holding stock appears to be overvalued.
The current stock price of HK$0.66 is trading 336.7% above its estimated GF Value™ of HK$0.15.
GuruFocus considers Broncus Holding to be Significantly Overvalued.
Key valuation signals for HKSE:02216:
Total Equity: HK$1,119.95 Mil
GF Value™: HK$0.15 vs. price of HK$0.66 (336.7% above fair value)
No single metric tells the full story. See the HKSE:02216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
43GF Score
Get the complete analysis for HKSE:02216
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02216 has been successfully added to your 
